PT  - JOURNAL ARTICLE
AU - National COVID Testing Scientific Advisory Panel
AU  - Adams, Emily R
AU  - Ainsworth, Mark
AU  - Anand, Rekha
AU  - Andersson, Monique I
AU  - Auckland, Kathryn
AU  - Baillie, J Kenneth
AU  - Barnes, Eleanor
AU  - Beer, Sally
AU  - Bell, John
AU  - Berry, Tamsin
AU  - Bibi, Sagida
AU  - Carroll, Miles
AU  - Chinnakannan, Senthil
AU  - Clutterbuck, Elizabeth
AU  - Cornall, Richard J
AU  - Crook, Derrick W
AU  - De Silva, Thushan
AU  - Dejnirattisai, Wanwisa
AU  - Dingle, Kate E
AU  - Dold, Christina
AU  - Espinosa, Alexis
AU  - Eyre, David W
AU  - Farmer, Helen
AU  - Fernandez Mendoza, Maria
AU  - Georgiou, Dominique
AU  - Hoosdally, Sarah J
AU  - Hunter, Alistair
AU  - Jeffrey, Katie
AU  - Klenerman, Paul
AU  - Knight, Julian
AU  - Knowles, Clarice
AU  - Kwok, Andrew J
AU  - Leuschner, Ullrich
AU  - Levin, Robert
AU  - Liu, Chang
AU  - Lopez-Camacho, Cesar
AU  - Martinez Garrido, Jose Carlos
AU  - Matthews, Philippa C
AU  - McGivern, Hannah
AU  - Mentzer, Alexander J
AU  - Milton, Jonathan
AU  - Mongkolsapaya, Juthathip
AU  - Moore, Shona C
AU  - Oliveira, Marta S
AU  - Pereira, Fiona
AU  - Perez Lopez, Elena
AU  - Peto, Timothy
AU  - Ploeg, Rutger J
AU  - Pollard, Andrew
AU  - Prince, Tessa
AU  - Roberts, David J
AU  - Rudkin, Justine K
AU  - Sanchez, Veronica
AU  - Screaton, Gavin R
AU  - Semple, Malcolm G
AU  - Skelly, Donal T
AU  - Slon-Campos, Jose
AU  - Smith, Elliot Nathan
AU  - Sobrino Diaz, Alberto Jose
AU  - Staves, Julie
AU  - Stuart, David
AU  - Supasa, Piyada
AU  - Surik, Tomas
AU  - Thraves, Hannah
AU  - Tsang, Pat
AU  - Turtle, Lance
AU  - Walker, A Sarah
AU  - Wang, Beibei
AU  - Washington, Charlotte
AU  - Watkins, Nicholas
AU  - Whitehouse, James
TI  - Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel
AID  - 10.1101/2020.04.15.20066407
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.15.20066407
4099  - http://medrxiv.org/content/early/2020/07/07/2020.04.15.20066407.short
4100  - http://medrxiv.org/content/early/2020/07/07/2020.04.15.20066407.full
AB  - Background The COVID-19 pandemic caused >1 million infections during January-March 2020. There is an urgent need for reliable antibody detection approaches to support diagnosis, vaccine development, safe release of individuals from quarantine, and population lock-down exit strategies. We set out to evaluate the performance of ELISA and lateral flow immunoassay (LFIA) devices.Methods We tested plasma for COVID (SARS-CoV-2) IgM and IgG antibodies by ELISA and using nine different LFIA devices. We used a panel of plasma samples from individuals who have had confirmed COVID infection based on a PCR result (n=40), and pre-pandemic negative control samples banked in the UK prior to December-2019 (n=142).Results ELISA detected IgM or IgG in 34/40 individuals with a confirmed history of COVID infection (sensitivity 85%, 95%CI 70-94%), vs. 0/50 pre-pandemic controls (specificity 100% [95%CI 93-100%]). IgG levels were detected in 31/31 COVID-positive individuals tested ≥10 days after symptom onset (sensitivity 100%, 95%CI 89-100%). IgG titres rose during the 3 weeks post symptom onset and began to fall by 8 weeks, but remained above the detection threshold. Point estimates for the sensitivity of LFIA devices ranged from 55-70% versus RT-PCR and 65-85% versus ELISA, with specificity 95-100% and 93-100% respectively. Within the limits of the study size, the performance of most LFIA devices was similar.Conclusions Currently available commercial LFIA devices do not perform sufficiently well for individual patient applications. However, ELISA can be calibrated to be specific for detecting and quantifying SARS-CoV-2 IgM and IgG and is highly sensitive for IgG from 10 days following first symptoms.Competing Interest StatementNoneFunding StatementThis study was supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, the UK Government Department of Health and Social Care and and grants from NIHR [award CO-CIN-01] and the Medical Research Council [grant MC_PC_19059]. DC, TEAP and ASW are supported by the National Institute for Health Research (NIHR) Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford in partnership with Public Health England (NIHR200915). Blood donor and QUOD samples were provided with support from NHS Blood and Transplant and the Medical Research Council UK. SKC is supported by Medical Research Council UK. TdS is funded by a Wellcome Trust Intermediate Clinical Fellowship (110058/Z/15/Z). DWE is a Robertson Foundation Fellow and NIHR Oxford BRC Senior Research Fellow. PM is a Wellcome Trust Clinical Research Fellow (110110/Z/15/Z) and NIHR Oxford BRC Senior Research Fellow. AM, PK, SCM, TPr, MGS and LT are supported by NIHR Health Protection Research Unit in Emerging and Zoonotic Infections (HPRU-EZI) at University of Liverpool in partnership with Public Health England (PHE), in collaboration with the University of Oxford and Liverpool School of Tropical Medicine (award number NIHR200907). EB, PK, AJP and ASW are NIHR Senior Investigators. PK (WT109965/MA) and GRS (095541/A/11/Z) are Wellcome Trust Senior Investigators. JR is supported by a Sir Henry Dale Fellowship, jointly funded by the Wellcome Trust and the Royal Society (Grant 101237/Z/13/B). The views expressed are the author(s) and are not necessarily those of the NHS, the NIHR, the UK Department of Health and Social Care, the MRC or PHE.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesResults generated for all samples and relevant metadata is provided in Table S7. https://doi.org/10.12688/wellcomeopenres.15927.1